Aurobindo and Intas among Final few Bidders for $1B Teva Generics Unit | Clinical Research Society
Mylan plays monkey-in-the-middle of hostile takeover battles | Fortune
Loss-Making Teva Pharmaceutical Industries Limited (NYSE:TEVA) Set To Breakeven - Simply Wall St News
Alex Ruus discusses Teva Pharmaceuticals - Video - BNN
Teva fined $519 million in U.S. for foreign bribes | News 7
Another Day. . .Another Pharmaceutical Acquisition: Teva and Mylan - AAM Company
We see a stable U.S. market place for our generics, says Teva Pharma CEO | Oakland News Now - Oakland News, SF Bay Area, East Bay, California, World
Mylan Should Try Teva On for Size - WSJ
Who's Kare Schultz, (NYSE:TEVA) New CEO In Charge Of Teva? | Benzinga
Will Teva Stock Rebound After A 10% Fall In A Month?
Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going? - WSJ
Teva slide could draw vultures but it won't be easy prey | The Times of Israel
Is A Fall Imminent For Teva Stock After Its Recent Rally?
July / August 2020 by Healthcare Sales and Marketing Magazine - Issuu
Is Teva Pharmaceutical a Safe Stock to Buy Now? | The Motley Fool
AstraZeneca Slumps on Report CEO Is Heading to Teva
TEVA: Can Teva Pharmaceutical Stock Continue to Rebound in 2021?
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
AstraZeneca's Soriot reportedly moving to top job at Teva
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
Mylan Should Try Teva On for Size - WSJ
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
If AstraZeneca CEO Soriot does take Teva's helm, what comes next? Megamerger talk, maybe | FiercePharma
